Status:
COMPLETED
A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects
Lead Sponsor:
Massachusetts General Hospital
Collaborating Sponsors:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
HIV-1 Infection
HIV Infections
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of the study is to find out whether an experimental autologous dendritic cell vaccine is safe, well tolerated, and whether it can strengthen the immune system's response to HIV.
Detailed Description
This is a randomized trial to evaluate whether mRNA-transfected dendritic cell vaccination is safe and immunogenic in HIV-infected participants who are on antiretroviral therapy.
Eligibility Criteria
Inclusion
- HIV-1 positive
- CD4+ T Cell count \>200
- Undetectable HIV viral load for 6 months prior to screening
- On antiretroviral treatment for 12 months prior to screening
Exclusion
- Hepatitis C positive
- Detectable HIV viral load within 6 months prior to study entry
- Females who are pregnant or nursing
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00833781
Start Date
August 1 2009
End Date
December 1 2013
Last Update
March 8 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Infectious Disease Unit; Massachusetts General Hospital
Boston, Massachusetts, United States, 02114